MBX Biosciences, Inc. MBX

Annual Quarterly

No annual revenue total was found in MBX Biosciences, Inc.'s SEC filings.

MBX Biosciences, Inc. (MBX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$81.9 million. As of Jun 30, 2026 it held $418.6 million in cash and investments and $3.3 million in total debt.

Revenue
—
Net income (TTM)
$-104.32M
Operating cash flow (TTM)
$-82.67M
Free cash flow (TTM)
$-85.20M
EPS (TTM)
$-2.41
Dividend per share
None
Shares outstanding
47.51M
+42.1% vs prior year
Net cash
$415.24M
as of Jun 30, 2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MBX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Carmel, IN
SEC filer status
, Emerging growth company
SEC CIK
1776111

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Operating income
-$98.1M
-$68.2M
Net income
-$87.0M
-$61.9M
Diluted EPS
-$2.38
-$5.82
Operating cash flow
-$79.9M
-$54.7M
Free cash flow
-$81.9M
-$55.6M
Total assets
$385.1M
$268.5M
Total liabilities
$15.9M
$11.1M
Stockholders' equity
$369.2M
$257.4M
Cash and investments
$373.7M
$262.1M
Total debt
$596,000
$171,000

Recent SEC filings

Form Description Filed Period
8-K Current report
Officer or director change
 Oct 22, 2026 Oct 20, 2026
8-K Current report
Regulation FD disclosure, Other events
 Aug 27, 2026 Aug 27, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations, Regulation FD disclosure, Other events
 Aug 6, 2026 Aug 6, 2026
8-K Current report
Officer or director change
 Jul 13, 2026 Jul 9, 2026
8-K Current report
Regulation FD disclosure, Other events
 Jun 12, 2026 Jun 12, 2026

All 230 MBX Biosciences, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.